Related Experiment Video

Updated: Sep 15, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha1, Sharmilan Thanendrarajan1, Aishee Bag2

  • 1University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.

Blood Advances
|July 17, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K

Related Experiment Videos

Last Updated: Sep 15, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry.

Cells·2026

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

Cancer·2026

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

The New England journal of medicine·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Blood advances·2026

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Blood·2026

National Alliance of Sickle Cell Disease Consensus Recommendations for Gene Therapy Implementation.

Blood advances·2026

Advancing Sickle Cell Disease Care Through Collaboration: the HHS and ASH Registry Leaders' Roundtable Initiative.

Blood advances·2026

Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation.

Blood advances·2026

Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12.

Blood advances·2026

Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma.

Blood advances·2026

Persistent Thromboxane Biosynthesis Despite Aspirin Therapy Predicts Preeclampsia.

Blood advances·2026

Cytological Findings and Diagnostic Pitfalls of a Rare Tumor Arising From a Rare Site: "The Story of Chondromyxoid Fibroma of Great Toe".

Diagnostic cytopathology·2026

Aging-enhanced accumulation of fibroblasts excludes oligodendrocytes in demyelinated lesions.

Journal of neuroinflammation·2026

Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies.

Molecular cancer·2026

Massive enlargement of a previously unrecognized bronchogenic cyst over 8 years with intracystic hemorrhage and complex surgical resection: a case report.

General thoracic and cardiovascular surgery cases·2026

Anti-thymocyte globulin triggers TNF-dependent cell death in T-cell acute lymphoblastic leukemia.

Nature communications·2026

Context Is Everything: Tumour-Type-Dependent Prioritisation of Tumour-Intrinsic, Microenvironmental and Host Determinants of Response to Immune-Checkpoint Blockade.

Critical reviews in oncology/hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us